Phase I trial of INT 767 in healthy volunteers

Trial Profile

Phase I trial of INT 767 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs INT 767 (Primary)
  • Indications Diabetic nephropathies; Hepatic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Aug 2016 According to an Intercept Pharmaceuticals media release, the company expects to complete this trial by end of the year 2016.
    • 05 May 2016 According to an Intercept Pharmaceuticals media release, the company expects to complete this trial in second half of 2016.
    • 30 Nov 2015 Status changed from planning to recruiting, according to an Intercept Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top